{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:03:05Z","timestamp":1776787385247,"version":"3.51.2"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The US Food and Drug Administration (FDA) has issued emergency use authorizations (EUAs) for monoclonal antibodies (mAbs) for nonhospitalized patients with mild or moderate coronavirus disease 2019 (COVID-19) disease and for individuals exposed to COVID-19 as postexposure prophylaxis. EUAs for oral antiviral drugs have also been issued. Due to increased demand because of the Delta variant, the federal government resumed control over the supply and asked states to ration doses. As future variants (eg, the Omicron variant) emerge, further rationing may be required. We identify relevant ethical principles (ie, benefiting people and preventing harm, equal concern, and mitigating health inequities) and priority groups for access to therapies based on an integrated approach to population health and medical factors (eg, urgently scarce healthcare workers, persons in disadvantaged communities hard hit by COVID-19). Using priority categories to allocate scarce therapies effectively operationalizes important ethical values. This strategy is preferable to the current approach of categorical exclusion or inclusion rules based on vaccination, immunocompromise status, or older age, or the ad hoc consideration of clinical risk factors.<\/jats:p>","DOI":"10.1093\/cid\/ciab1039","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:13:09Z","timestamp":1639599189000},"page":"e529-e533","source":"Crossref","is-referenced-by-count":10,"title":["Fair Allocation of Scarce Therapies for Coronavirus Disease 2019 (COVID-19)"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-9209","authenticated-orcid":false,"given":"Govind","family":"Persad","sequence":"first","affiliation":[{"name":"Sturm College of Law, University of Denver , Denver, Colorado , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica E","family":"Peek","sequence":"additional","affiliation":[{"name":"University of Chicago , Chicago, Illinois , USA and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema K","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University , Evanston, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"2022082503001703100_CIT0001","author":"Food and Drug Administration.","year":"2020"},{"key":"2022082503001703100_CIT0002","author":"McGinley","year":"2020"},{"key":"2022082503001703100_CIT0003","author":"US Department of Health and Human Services.","year":"2021"},{"key":"2022082503001703100_CIT0004","article-title":"A tale of two antiviral targets\u2014and the COVID-19 drugs that bind them","author":"Cully","year":"2021","journal-title":"Nature"},{"key":"2022082503001703100_CIT0005","author":"U.S. Department of Health and Human Services.","year":"2021"},{"key":"2022082503001703100_CIT0006","author":"National Institutes of Health."},{"key":"2022082503001703100_CIT0007","doi-asserted-by":"crossref","first-page":"923","DOI":"10.15585\/mmwr.mm6928e1","article-title":"Characteristics of persons who died with COVID-19-United States, February 12\u2013May 18, 2020","volume":"69","author":"Wortham","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082503001703100_CIT0008","doi-asserted-by":"crossref","first-page":"e1003402","DOI":"10.1371\/journal.pmed.1003402","article-title":"Variation in racial\/ethnic disparities in COVID-19 mortality by age in the United States: a cross-sectional study","volume":"17","author":"Bassett","year":"2020","journal-title":"PLoS Med"},{"key":"2022082503001703100_CIT0009","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.15585\/mmwr.mm6949a3","article-title":"COVID-19 mortality among American Indian and Alaska native persons\u201414 states, January\u2013June 2020","volume":"69","author":"Arrazola","year":"2020","journal-title":"Morb Mortal Wkly Rep"},{"key":"2022082503001703100_CIT0010","doi-asserted-by":"crossref","first-page":"eabj2099","DOI":"10.1126\/sciadv.abj2099","article-title":"Geographically targeted COVID-19 vaccination is more equitable and averts more deaths than age-based thresholds alone","volume":"7","author":"Wrigley-Field","year":"2021","journal-title":"Sci Adv"},{"key":"2022082503001703100_CIT0011","author":"Roberts","year":"2018"},{"key":"2022082503001703100_CIT0012","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1001\/jama.2016.4226","article-title":"The association between income and life expectancy in the United States, 2001\u20132014","volume":"315","author":"Chetty","year":"2016","journal-title":"JAMA"},{"key":"2022082503001703100_CIT0013","author":"Mueller","year":"2021"},{"key":"2022082503001703100_CIT0014","author":"NYC Health."},{"key":"2022082503001703100_CIT0015","author":"Ndugga","year":"2021"},{"key":"2022082503001703100_CIT0016","first-page":"57","article-title":"Prevalence of undiagnosed HIV infection among persons aged \u226513 years\u2014National HIV surveillance system, United States, 2005\u20132008","volume":"61","author":"Chen","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022082503001703100_CIT0017","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s11606-018-4471-1","article-title":"Racial and ethnic disparities in diagnosis of chronic medical conditions in the USA","volume":"33","author":"Kim","year":"2018","journal-title":"J General Int Med"},{"key":"2022082503001703100_CIT0018","author":"Centers for Disease Control.","year":"2021"},{"key":"2022082503001703100_CIT0019","year":"2020"},{"key":"2022082503001703100_CIT0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.athoracsur.2020.04.080","article-title":"Ethical guidelines and moral distress during the COVID-19 pandemic: the trainees\u2019 perspective","volume":"112","author":"Han","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"2022082503001703100_CIT0021","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0969733020981748","article-title":"Priority-setting dilemmas, moral distress and support experienced by nurses and physicians in the early phase of the COVID-19 pandemic in Norway","volume":"28","author":"Miljeteig","year":"2021","journal-title":"Nurs Ethics"},{"key":"2022082503001703100_CIT0022","author":"Centers for Disease Control."},{"key":"2022082503001703100_CIT0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jama.2020.25053","article-title":"The ethics of continuing placebo in SARS-CoV-2 vaccine trials","volume":"325","author":"Rid","year":"2021","journal-title":"JAMA"},{"key":"2022082503001703100_CIT0024","author":"National Institutes of Health."},{"key":"2022082503001703100_CIT0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.08.003","article-title":"A novel approach to equitable distribution of scarce therapeutics: institutional experience implementing a reserve system for allocation of Covid-19 monoclonal antibodies","author":"Rubin","year":"2021","journal-title":"Chest"},{"key":"2022082503001703100_CIT0026","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chest.2020.12.019","article-title":"Categorized priority systems: a new tool for fairly allocating scarce medical resources in the face of profound social inequities","volume":"159","author":"S\u00f6nmez","year":"2021","journal-title":"Chest"},{"key":"2022082503001703100_CIT0027","doi-asserted-by":"crossref","first-page":"e2023020","DOI":"10.1001\/jamanetworkopen.2020.23020","article-title":"US adults\u2019 preferences for public allocation of a vaccine for coronavirus disease 2019","volume":"3","author":"Gollust","year":"2020","journal-title":"JAMA Network Open"},{"key":"2022082503001703100_CIT0028","doi-asserted-by":"crossref","first-page":"e217943","DOI":"10.1001\/jamanetworkopen.2021.7943","article-title":"Public perspectives on COVID-19 vaccine prioritization","volume":"4","author":"Persad","year":"2021","journal-title":"JAMA Network Open"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab1039\/42325289\/ciab1039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e529\/45513550\/ciab1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/1\/e529\/45513550\/ciab1039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T03:01:54Z","timestamp":1661396514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/1\/e529\/6469906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,18]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab1039","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,12,18]]}}}